Company intelligence / Profile preview
Verona Pharma
London, England, United Kingdomveronapharma.gcs-web.com ↗
- Ownership
- Public · VRNA
- Employees
- ~209
- Development stage
- Commercial
01
Overview
Verona Pharma’s lead product, Ohtuvayre™ (ensifentrine), received FDA approval in June 2024 as a maintenance treatment for COPD in adults. The company reported strong commercial uptake with $71.3 million in net sales of Ohtuvayre in Q1 of 2025 and ~25,000 prescriptions filled. Ensifentrine demonstrated statistically significant improvements in lung function and reduced exacerbation rates in Phase III trials. Additional formulations and indications are advancing through Phase II development
- Therapeutic areas
- Pulmonology
- Modalities
- Small molecules (notably ensifentrine, a dual PDE3/PDE4 inhibitor)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Nuance Pharma Limited — agreement to develop/commercialize ensifentrine in Greater ChinaStrategic financing agreements with Oaktree Capital Management and OMERS Life Sciences
04
Financials
- Market cap
- $72.7B
- Total revenue
- $75.1M
- Enterprise value
- $72.5B
Beyond the preview
Go deeper on Verona Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Verona Pharma.